Pierre D’Arbigny

578 total citations
19 papers, 451 citations indexed

About

Pierre D’Arbigny is a scholar working on Pathology and Forensic Medicine, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Pierre D’Arbigny has authored 19 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Pediatrics, Perinatology and Child Health and 3 papers in Molecular Biology. Recurrent topics in Pierre D’Arbigny's work include Cardiac Ischemia and Reperfusion (5 papers), Analytical Chemistry and Chromatography (3 papers) and Epilepsy research and treatment (3 papers). Pierre D’Arbigny is often cited by papers focused on Cardiac Ischemia and Reperfusion (5 papers), Analytical Chemistry and Chromatography (3 papers) and Epilepsy research and treatment (3 papers). Pierre D’Arbigny collaborates with scholars based in France, United States and Spain. Pierre D’Arbigny's co-authors include Sylvia Pietri, Marcel Culcasi, J Séguin, Frederic Schwartz, Jean‐Marc Kamenka, F Ohanna, Manuel Gaviria, Katy Drieu, J.M. Gandon and Alain Lieury and has published in prestigious journals such as Brain Research, Free Radical Biology and Medicine and International Journal of Pharmaceutics.

In The Last Decade

Pierre D’Arbigny

19 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre D’Arbigny France	9	142	120	114	102	84	19	451
Juan Zhu China	15	95 0.7×	78 0.7×	51 0.4×	110 1.1×	236 2.8×	28	682
Youn-Jung Kim South Korea	11	115 0.8×	66 0.6×	127 1.1×	28 0.3×	80 1.0×	30	568
Isabelle Jamme France	8	63 0.4×	77 0.6×	28 0.2×	65 0.6×	135 1.6×	12	375
Jayanarayanan Sadanandan India	12	82 0.6×	66 0.6×	75 0.7×	41 0.4×	93 1.1×	22	430
Sihua Qi China	15	34 0.2×	97 0.8×	82 0.7×	145 1.4×	283 3.4×	28	625
Jingye Wang China	11	41 0.3×	77 0.6×	151 1.3×	199 2.0×	237 2.8×	17	678
Xuying Li China	14	205 1.4×	74 0.6×	144 1.3×	184 1.8×	208 2.5×	37	702
J. R. Rapin France	14	70 0.5×	96 0.8×	18 0.2×	102 1.0×	121 1.4×	46	696
C. Di Massimo Italy	17	64 0.5×	29 0.2×	75 0.7×	94 0.9×	118 1.4×	33	708

Countries citing papers authored by Pierre D’Arbigny

Since Specialization

Citations

This map shows the geographic impact of Pierre D’Arbigny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre D’Arbigny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre D’Arbigny more than expected).

Fields of papers citing papers by Pierre D’Arbigny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre D’Arbigny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre D’Arbigny. The network helps show where Pierre D’Arbigny may publish in the future.

Co-authorship network of co-authors of Pierre D’Arbigny

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre D’Arbigny. A scholar is included among the top collaborators of Pierre D’Arbigny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre D’Arbigny. Pierre D’Arbigny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Artime, Esther, Irene M. Shui, Ignacio Méndez, et al.. (2019). Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet. Pharmacoepidemiology and Drug Safety. 29(1). 103–110. 2 indexed citations

Lepeintre, J.-F., Pierre D’Arbigny, J.-F. Mathé, et al.. (2008). NEUROPROTECTIVE EFFECT OF GACYCLIDINE. 6 indexed citations

Lepeintre, J.-F., Pierre D’Arbigny, J.-F. Mathé, et al.. (2004). Neuroprotective effect of gacyclidine: A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neurochirurgie. 50(2-3). 83–95. 19 indexed citations

Hoizey, Guillaume, Matthieu L. Kaltenbach, Sylvain Dukic, et al.. (2001). Pharmacokinetics of gacyclidine enantiomers in plasma and spinal cord after single enantiomer administration in rats. International Journal of Pharmaceutics. 229(1-2). 147–153. 5 indexed citations

Hoizey, Guillaume, Matthieu L. Kaltenbach, Sylvain Dukic, et al.. (2001). Distribution of Gacyclidine Enantiomers after Experimental Spinal Cord Injury in Rats: Possible Involvement of an Active Transport System. Journal of Pharmaceutical Sciences. 90(1). 70–78. 2 indexed citations

Feldblum, Sophie, et al.. (2000). Efficacy of a New Neuroprotective Agent, Gacyclidine, in a Model of Rat Spinal Cord Injury. Journal of Neurotrauma. 17(11). 1079–1093. 30 indexed citations

Gaviria, Manuel, et al.. (2000). Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats. Brain Research. 874(2). 200–209. 67 indexed citations

Gaviria, Manuel, et al.. (2000). Neuroprotective Effects of Gacyclidine After Experimental Photochemical Spinal Cord Lesion in Adult Rats: Dose-Window and Time-Window Effects. Journal of Neurotrauma. 17(1). 19–30. 35 indexed citations

Hoizey, Guillaume, Matthieu L. Kaltenbach, Sylvain Dukic, et al.. (2000). Distribution of Gacyclidine Enantiomers in Spinal Cord Extracellular Fluid. Pharmaceutical Research. 17(2). 148–153. 6 indexed citations

10.

Hoizey, Guillaume, et al.. (1999). Modified gas chromatographic–mass spectrometric assay for the determination of gacyclidine enantiomers in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 731(2). 317–322. 1 indexed citations

11.

Hoizey, Guillaume, et al.. (1999). Sensitive gas chromatographic–mass spectrometric method for the determination of gacyclidine in rat plasma and spinal cord dialyzates. The Analyst. 124(12). 1761–1764. 1 indexed citations

12.

Pietri, Sylvia, J Séguin, Pierre D’Arbigny, Katy Drieu, & Marcel Culcasi. (1997). Ginkgo biloba Extract (EGb 761) Pretreatment Limits Free Radical Oxidative Stress in Patients Undergoing Coronary Bypass Surgery. Cardiovascular Drugs and Therapy. 11(2). 121–131. 69 indexed citations

13.

Hoizey, Guillaume, et al.. (1997). Determination of gacyclidine enantiomers in human plasma by gas chromatography–mass spectrometry using selected-ion monitoring. Journal of Chromatography B Biomedical Sciences and Applications. 704(1-2). 167–174. 4 indexed citations

14.

Pons, Catherine, et al.. (1997). Effect of <i>Ginkgo bilob</i><i>a</i> Extract (EGb 761) on the Vasospastic Response of Mouse Cutaneous Arterioles to Platelet Activation. PubMed. 17(2). 61–66. 8 indexed citations

15.

Schwartz, Frederic, et al.. (1996). EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure.. PubMed. 67(5). 445–52. 59 indexed citations

16.

Dumont, Éric C., Pierre D’Arbigny, & A. Nouvelot. (1995). Protection of polyunsaturated fatty acids against iron-dependent lipid peroxidation by a Ginkgo biloba extract (EGb 761).. PubMed. 17(2). 83–8. 13 indexed citations

17.

Pietri, Sylvia, J Séguin, Pierre D’Arbigny, & Marcel Culcasi. (1994). Ascorbyl free radical: A noninvasive marker of oxidative stress in human open-heart surgery. Free Radical Biology and Medicine. 16(4). 523–528. 57 indexed citations

18.

Allain, H., et al.. (1993). Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects.. PubMed. 15(3). 549–58. 65 indexed citations

19.

Luthringer, R., et al.. (1992). EEG AND EPs MAPPING PROFILE OF GINKGO BILOBA EXTRACT (EGb 761). Clinical Neuropharmacology. 15. 152B–152B. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact